Commercialization of Cannabinoids, Terpenes and Flavonoid (CTF kits) derived from Cannabis
Plants
Research has well-established the unequivocal roles of synergistic effects of enhancing bio
functionalities of cannabis derived cannabinoids, when mixed with varying proportion of terpenes and
flavonoids, or each other (Entourage effect). Thus, the adult recreational, the medical, therapeutic or drug
discovery markets all do have the common need for specific, pure and safe formulations in isolation and in
various titrating combinations of a large repertoire of bioactive extracts and appropriate high throughput
designed, clever screening assays.
Specific Aims
The primary goal of the Phase I research proposal is to provide exploratory modular
panels containing cannabinoids, terpenes and flavonoid (CTF) extracts in a 96 ELISA plate
format for R&D kits. Identification and customization of therapeutic and additional cannabis components
including terpenoids and flavonoids also have analgesic properties that may be significant.
Specific Aim 1 (a): Synthesize, Isolate or Extract to Develop the cannabinoid, terpene and
flavone CTF panels as R&D kits consisting of Cannabis plant isolated bioactive extracts of 8
cannabinoid, 21 terpenes and 7 flavonoids in a checkerboard format to investigate synergistic
effectiveness for discovery screening in laboratory based cellular functional assays and in olfactory
panel testing of odor preferences.1. The Cannabinoid Panel ((-)-Δ9-Transtetrahydrocannabinol THC, Tetrahydrocannabivarin THCV,
Cannabidiol CBD, Cannabigerol CBG, Cannabinol CBN, Cannabichromene CBC)
2. The Terpene Panel (Borneol, delta 3-Carene, Caryophyllene Oxide, trans-Carophyllene,
Eucalyptol , Limonene, Linalool, Myrcene, alpha Pinene, beta Pinene, Terpineo, alpha-Terpinolene,
beta-Farnesene, Fenchyl Alcohol, Camphene, alpha-Humulene, beta-Phellandrene, cis-Ocimene,
trans-Ocimene, alpha-Bergamotene, beta-Selinene)
3. The Flavone Panel (Quercetin, Luteolin, Kaempferol, Cannflavin A, Cannflavin B, Apigenin, beta-
Sitosterol)
Specific Aim 1 (b): Develop and maintain an electronic Cannabis Database, that will
retain a detailed track of all our SOP documentation in Phase I prepared reagents and
characterization of the standards needed to quantitate these CTF panel identifiable from their initial
batch preparation and their associated data that they will generate. The operation of Specific Aims 1
will require a documentation platform that we will utilize to perform experiments and also generate a
prototype module for data gathering. We will set up and provide a cloud-based secure system in
which, eventually, the data can be an accessed in an open source cloud-hosted environment to
encourage data informatics through the web. The ultimate purpose of this Cannabis Database will be
an encompassing repertoire linking the genetics, cultivation, manufacture and utility of cannabis
derived medical and social relating data to an individual’s personal record while maintaining strictest
confidentiality.
Specific Aim 2: Internet-based marketing to reach out through e-mail campaigns to all
Cannabis related R&D funded (including NIH related R01s identified using NIH Researcher
databases) for collaborative partnerships with our reagent offerings in partner’s assays and their
willingness to share data in return. The legitimate use of marijuana for several medical indications
has far outpaced the medical and clinical evaluation of marijuana and specific cannabinoids for
different medical uses. Our strategy of providing our own standards and calibrators early in the industry
(for e.g. we will send the calibrators as samples for voluntary participation of initial intra laboratory data
assessment laboratories doing marijuana testing) we will strive to be the single source provider of national
clinical requirements by providing FDA compliant products. Also note that some of the cannabis derived
reagent could classify under GRAS and be commercially sold as supplements.
Specific Aim 3: It is our intent to keep a detailed track of all our reagents identifiable from
their initial batch preparation and the plethora of data they will generate in a central, cloud based
Cannabis Database. We will provide this data in an open source cloud hosted environment to encourage